Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

Summary

This is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo. Study subjects will have the diagnosis of mild dementia of the Alzheimer's type. Subjects may be taking approved medication for Alzheimer's disease provided the dose has been stable for at least 6 months.

Timeline

Start

2006-05

Primary completion

—

Completion

2008-12

Outcome

Outcome not reported

Stopped: “Myriad has discontinued the development of Flurizan.”

Drugs

Indications